PBFT02 administration resulted in improvements in two disease progression biomarkers, as compared to natural history, reducing brain atrophy and stabilizing plasma NfL levels  FDA feedback from recent ...

Hydrocephalus is prevalent worldwide and can affect people of any age. According to the Hydrocephalus Association, one million Americans suffer from the condition and some 25 million worldwide. The ...

Emerging research has identified a potential biological connection between autism spectrum disorder and Alzheimer's disease, ...

Hydrocephalus, commonly referred to as "water on the brain," is a dangerous and potentially deadly condition that can harm ...

Replimune received a second FDA complete response letter for RP1 in advanced melanoma, raising questions about the viability of its oncolytic immunotherapy program. Replimune Group received a complete ...

Learn how G-CSF and trilaciclib help prevent febrile neutropenia in extensive-stage SCLC, with NCCN-backed timing tips and ...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., April 09, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; ...

Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals ...

Shares of Ultragenyx Pharmaceutical RARE rose 5% after the company announced that the FDA has accepted its resubmitted biologics license application (BLA) seeking accelerated approval for AAV gene ...

Please provide your email address to receive an email when new articles are posted on . IBC-Ab002 treatment doses ranged from 1 mg/kg to 30 mg/kg and were given four times. No safety concerns arose in ...

BOSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 ...